| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Martha Sajatovic, Subramoniam Madhusoodanan, Matthew A Fuller, Lakynetiew Aulakh, Daniel B Keato. Risperidone for bipolar disorders. Expert review of neurotherapeutics. vol 5. issue 2. 2006-04-14. PMID:15853488. |
this drug profile of risperidone for bipolar disorder will address the chemistry, pharmacodynamics, pharmacokinetics and metabolism of risperidone, clinical trials in bipolar disorder, postmarketing surveillance, safety, tolerability and regulatory issues. |
2006-04-14 |
2023-08-12 |
Not clear |
| Robert M Post, Joseph R Calabres. Bipolar depression: the role of atypical antipsychotics. Expert review of neurotherapeutics. vol 4. issue 6 Suppl 2. 2006-04-14. PMID:16279863. |
the atypical agents olanzapine, risperidone and quetiapine have demonstrated efficacy against the manic phase of bipolar disorder and appear also to have potential in the depressive phase. |
2006-04-14 |
2023-08-12 |
Not clear |
| Eduard Viet. Maintenance therapy for bipolar disorder: current and future management options. Expert review of neurotherapeutics. vol 4. issue 6 Suppl 2. 2006-04-14. PMID:16279865. |
numerous treatments are available for the management of bipolar disorder, including lithium, divalproex, conventional antipsychotics, the anticonvulsant lamotrigine, and several newer atypical agents, including olanzapine, risperidone, quetiapine, ziprasidone and aripiprazole. |
2006-04-14 |
2023-08-12 |
Not clear |
| Roger S McIntyre, Deborah A Mancini, Janaki Srinivasan, Sonia McCann, Jakub Z Konarski, Sidney H Kenned. The antidepressant effects of risperidone and olanzapine in bipolar disorder. The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique. vol 11. issue 2. 2006-04-06. PMID:15520475. |
the antidepressant effects of risperidone and olanzapine in bipolar disorder. |
2006-04-06 |
2023-08-12 |
Not clear |
| Joseph Biederman, Eric Mick, Janet Wozniak, Megan Aleardi, Thomas Spencer, Stephen V Faraon. An open-label trial of risperidone in children and adolescents with bipolar disorder. Journal of child and adolescent psychopharmacology. vol 15. issue 2. 2006-01-13. PMID:15910215. |
an open-label trial of risperidone in children and adolescents with bipolar disorder. |
2006-01-13 |
2023-08-12 |
Not clear |
| Joseph Biederman, Eric Mick, Janet Wozniak, Megan Aleardi, Thomas Spencer, Stephen V Faraon. An open-label trial of risperidone in children and adolescents with bipolar disorder. Journal of child and adolescent psychopharmacology. vol 15. issue 2. 2006-01-13. PMID:15910215. |
the aim of this study was to evaluate the potential of risperidone as a treatment of pediatric bipolar disorder. |
2006-01-13 |
2023-08-12 |
Not clear |
| Eduard Vieta, Jose M Goikole. Atypical antipsychotics: newer options for mania and maintenance therapy. Bipolar disorders. vol 7 Suppl 4. 2005-12-07. PMID:15948764. |
through a review of randomized controlled trials for five commonly used atypical drugs, olanzapine, risperidone, quetiapine, ziprasidone and aripiprazole, this article evaluates their efficacy in the acute and maintenance phases of bipolar disorder. |
2005-12-07 |
2023-08-12 |
Not clear |
| Joseph Biederman, Eric Mick, Paul Hammerness, Theresa Harpold, Megan Aleardi, Meghan Dougherty, Janet Woznia. Open-label, 8-week trial of olanzapine and risperidone for the treatment of bipolar disorder in preschool-age children. Biological psychiatry. vol 58. issue 7. 2005-11-30. PMID:16239162. |
open-label, 8-week trial of olanzapine and risperidone for the treatment of bipolar disorder in preschool-age children. |
2005-11-30 |
2023-08-12 |
Not clear |
| Joseph Biederman, Eric Mick, Paul Hammerness, Theresa Harpold, Megan Aleardi, Meghan Dougherty, Janet Woznia. Open-label, 8-week trial of olanzapine and risperidone for the treatment of bipolar disorder in preschool-age children. Biological psychiatry. vol 58. issue 7. 2005-11-30. PMID:16239162. |
to evaluate short-term safety and efficacy of atypical antipsychotics in a single-site, prospective, open-label, 8-week study of risperidone and olanzapine monotherapy in preschoolers with bipolar disorder (bpd). |
2005-11-30 |
2023-08-12 |
Not clear |
| Ricardo Alberto Moreno, Doris Hupfeld Moreno, Márcia Britto de Macedo Soares, Roberto Ratzk. [Anticonvulsants and antipsychotics in the treatment of bipolar disorder]. Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999). vol 26 Suppl 3. 2005-10-26. PMID:15597138. |
the available literature on the use of anticonvulsants (valproate, carbamazepine, oxcarbazepine, lamotrigine, gabapentin, topiramate, clonazepam) and atypical antipsychotics (clozapine, risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole) for acute and prophylactic treatment of bipolar disorder was reviewed. |
2005-10-26 |
2023-08-12 |
Not clear |
| Lakshmi N Yatha. Atypical antipsychotics for bipolar disorder. The Psychiatric clinics of North America. vol 28. issue 2. 2005-09-29. PMID:15826735. |
similarly, long-term studies are needed to ascertain the role of risperidone, quetiapine, and ziprasidone in the maintenance treatment of bipolar disorder. |
2005-09-29 |
2023-08-12 |
Not clear |
| Frank Gianfrancesco, Jacqueline Pesa, Ruey-Hua Wan. Comparison of mental health resources used by patients with bipolar disorder treated with risperidone, olanzapine, or quetiapine. Journal of managed care pharmacy : JMCP. vol 11. issue 3. 2005-07-12. PMID:15804206. |
comparison of mental health resources used by patients with bipolar disorder treated with risperidone, olanzapine, or quetiapine. |
2005-07-12 |
2023-08-12 |
Not clear |
| Frank Gianfrancesco, Jacqueline Pesa, Ruey-Hua Wan. Comparison of mental health resources used by patients with bipolar disorder treated with risperidone, olanzapine, or quetiapine. Journal of managed care pharmacy : JMCP. vol 11. issue 3. 2005-07-12. PMID:15804206. |
the atypical antipsychotics, risperidone, olanzapine, and quetiapine, have been approved by the u.s. food and drug administration for treatment of mania associated with bipolar disorder. |
2005-07-12 |
2023-08-12 |
Not clear |
| Frank Gianfrancesco, Jacqueline Pesa, Ruey-Hua Wan. Comparison of mental health resources used by patients with bipolar disorder treated with risperidone, olanzapine, or quetiapine. Journal of managed care pharmacy : JMCP. vol 11. issue 3. 2005-07-12. PMID:15804206. |
we compared charges for other mental health services associated with risperidone, olanzapine, and quetiapine treatment of patients with bipolar disorder to assess whether there were significant differences between these therapies. |
2005-07-12 |
2023-08-12 |
Not clear |
| Peter F Buckle. Second-generation antipsychotic medications in the treatment of mood disorders: focus on aripiprazole. Drugs of today (Barcelona, Spain : 1998). vol 41. issue 1. 2005-06-02. PMID:15753965. |
information about the agents clozapine, risperidone, olanzapine, quetiapine, ziprasidone and aripiprazole in terms of their efficacy and tolerability in bipolar disorder is now available. |
2005-06-02 |
2023-08-12 |
Not clear |
| Martha Sajatovic, Subramoniam Madhusoodanan, Nicoleta Coconce. Managing bipolar disorder in the elderly: defining the role of the newer agents. Drugs & aging. vol 22. issue 1. 2005-05-13. PMID:15663348. |
olanzapine, risperidone, quetiapine, ziprasidone and aripiprazole are atypical antipsychotics that have been approved by the us fda for the treatment of bipolar disorder; however, there are no published, controlled trials with atypical antipsychotics specific to mania in geriatric patients. |
2005-05-13 |
2023-08-12 |
Not clear |
| Martha Sajatovic, Subramoniam Madhusoodanan, Nicoleta Coconce. Managing bipolar disorder in the elderly: defining the role of the newer agents. Drugs & aging. vol 22. issue 1. 2005-05-13. PMID:15663348. |
preliminary reports on the use of clozapine, risperidone, olanzapine and quetiapine suggest a role for the use of these agents in late-life bipolar disorder. |
2005-05-13 |
2023-08-12 |
Not clear |
| Charles L Bowde. Atypical antipsychotic augmentation of mood stabilizer therapy in bipolar disorder. The Journal of clinical psychiatry. vol 66 Suppl 3. 2005-04-22. PMID:15762830. |
recent clinical studies have shown that augmentation therapy with the atypical antipsychotics risperidone, olanzapine, quetiapine, and ziprasidone is effective in long-term maintenance treatment, and preliminary evidence is emerging that use of atypicals with mood stabilizers can help control the depressive phase of bipolar disorder. |
2005-04-22 |
2023-08-12 |
Not clear |
| M-N Vacheron-Trystram, A Braitman, S Cheref, L Auffra. [Antipsychotics in bipolar disorders]. L'Encephale. vol 30. issue 5. 2005-03-22. PMID:15627046. |
currently, a number of prospective studies are available with clozapine, risperidone and olanzapine in the treatment of bipolar disorder. |
2005-03-22 |
2023-08-12 |
human |
| M-N Vacheron-Trystram, A Braitman, S Cheref, L Auffra. [Antipsychotics in bipolar disorders]. L'Encephale. vol 30. issue 5. 2005-03-22. PMID:15627046. |
a naturalistic comparison of clozapine, risperidone and olanzapine in the treatment of bipolar disorder suggests that the efficacy and tolerability of the three treatments are similar. |
2005-03-22 |
2023-08-12 |
human |